# Advisor Review - GPT-5.2

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-27T13:54:33.504511
**Route:** OpenRouter + LaTeX
**Paper Hash:** 50628755b3b82b68
**Tokens:** 16057 in / 1661 out
**Response SHA256:** 77b1b31a16e8eb40

---

## 1) Data–Design Alignment (Critical)

### Treatment timing vs. data coverage
- Treatment (UC full service rollout): **Nov 2015–Dec 2018**
- Outcome panel: **Jan 2013–Dec 2019**
- This is aligned: **max(treatment date) ≤ max(data date)**, and there is a meaningful pre-period.

### Post-treatment observations
- For staggered DiD: every treated cohort (through **Dec 2018**) has post-treatment data through **Dec 2019**.
- “Never-treated” group is defined as not treated by **Dec 2018**; since the panel continues through 2019, these units remain untreated throughout the observation window. This is coherent.

### Treatment definition consistency
- The treatment is consistently described as **UC “full service” adoption date** (not “live service”).
- Counts of LAs are consistent across the paper:
  - 336 coded → 4 dropped → **332** in panel
  - **289 treated**, **43 never-treated**
  - Balanced panel math checks (e.g., 332×84 = 27,888).

No fatal data–design misalignment found.

---

## 2) Regression Sanity (Critical)

I checked every table with regression-like output:

### Table 4 (Main results), Table 5 (Robustness), Table A2 (Extended robustness)
- Coefficients are small and plausible for a rate outcome.
- Standard errors are plausible and **nowhere near** thresholds that would indicate broken specifications (no SEs that dwarf coefficients by 100× in a way suggestive of numerical failure; no gigantic SEs).
- No impossible fit statistics are reported (no R² shown, so no R² violations).
- No “NA / NaN / Inf” entries.

**Minor note (not fatal under your rules):** several placebo-sector entries show “0.000 (0.000)”. That can be legitimate if the sector outcome is extremely rare and the estimate is rounded to three decimals. It is not, by itself, a regression-output failure.

No fatal regression sanity violations found.

---

## 3) Completeness (Critical)

- No placeholders like **TBD/TODO/XXX/NA** appear in tables.
- Regression tables report **coefficients, SEs, and N**.
- The text references tables/figures that are present in the LaTeX source (even if the PDF figure files themselves aren’t embedded here, that’s not a “missing figure reference” problem within the source).

No fatal completeness problems found.

---

## 4) Internal Consistency (Critical)

- Sample period is consistently **Jan 2013–Dec 2019**.
- Pre-period described as **Jan 2013–Oct 2015 (34 months)** and the N in Table 1 matches:
  - Treated pre-period N = 289×34 = **9,826**
  - Never-treated pre-period N = 43×34 = **1,462**
- Main ATT number in abstract (ATT = **0.005**, p = **0.79**) matches Table 4 Panel A (0.005, p=0.793).

One potential *interpretation* inconsistency I checked (but it does **not** rise to a fatal error under your criteria): the discussion of which cohorts identify the “MIF binding (12+m)” coefficient is a bit loose (it’s true that later-treated units contribute fewer months in the 12+ window), but the design is not mathematically impossible and does not create a timing/data contradiction.

No fatal internal-consistency violations found.

---

ADVISOR VERDICT: PASS